Amyloidosis, Diarrhea, and a Somatostatin Analogue
Authors: Carolyn R. O'Connor, Thomas M. O'Dorisio
Journal: Annals of Internal Medicine (1989)

Letters and Corrections15 April 1989Amyloidosis, Diarrhea, and a Somatostatin AnalogueCarolyn R. O'Connor, MD, Thomas M. O'Dorisio, MDCarolyn R. O'Connor, MDSearch for more papers by this author, Thomas M. O'Dorisio, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-8-665 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Initially, somatostatin analogues were reported to be effective in treating secretory diarrhea that occurs in Werner-Morrison syndrome and carcinoid syndrome (1). Recently, a long-acting somatostatin analogue (SMS 201-995, octreotide acetate, Sandostatin) has been reported to be beneficial in treating other types of diarrhea (2, 3). We report the case of a patient with primary systemic amyloidosis who had diarrhea refractory to conventional treatment and whose symptoms were controlled with administration of SMS 201-995.A 78-year-old man had a 6-month history of weight loss, anorexia, and six watery bowel movements daily. There was no family history of amyloidosis...References1. Maton P. Use in patients with gut neuroendocrine tumors, pp 41-44. In: Gordon P, moderator. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50. MedlineGoogle Scholar2. RobinsonFogel ER. SMS 201-995, a somatostatin analogue and diarrhea in the acquired immunodeficiency syndrome. Ann Intern Med. 1988;109:680-1. LinkGoogle Scholar3. Go V. Therapeutic use in non-malignant diseases of the gastrointestinal tract, pp 44-47. In: Gordon P, moderator. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormonesecreting tumors of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50. MedlineGoogle Scholar4. YamadaHatakeyamaTsukagoshi MSH. Gastrointestinal amyloid deposition in AL (primary or myeloma-associated) and AA (secondary) amyloidosis. Hum Pathol. 1985;16:1206-21. CrossrefMedlineGoogle Scholar5. BattleRubinCohenSnape WMSW. Gastrointestinal motility dysfunction in amyloidosis. N Engl J Med. 1979;301:24-5. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPharmacological Management of DiarrheaGastrointestinal Manifestations of AmyloidosisSevere protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotideChronic Respiratory Distress, Dyspepsia, and Diarrhea: What Is the Connection?Expanding uses of octreotideUSE OF GUT PEPTIDE RECEPTOR AGONISTS AND ANTAGONISTS IN GASTROINTESTINAL DISEASESOctreotide in the Treatment of Disorders of the Gastrointestinal SystemOctreotide for Diarrhea in AmyloidosisLung T. Yam, MD, Socorro B. Oropilla, MDSomatostatin and octreotide in gastroenterologyNutritional Support of Patients with AIDSAmyloidosisSevere posthemicolectomy diarrhea: Evaluation and treatment with SMS 201-995Treatment of endocrine and nonendocrine secretory diarrheal states with Sandostatin® 15 April 1989Volume 110, Issue 8Page: 665-666KeywordsAmyloidosisDiarrheaSomatostatinWeight loss Issue Published: 15 April 1989 PDF DownloadLoading ...